4/8
07:05 pm
okyo
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 [Yahoo! Finance]
Medium
Report
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 [Yahoo! Finance]
4/8
07:00 pm
okyo
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
Medium
Report
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
4/2
07:05 am
okyo
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery [Yahoo! Finance]
Low
Report
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery [Yahoo! Finance]
4/2
07:00 am
okyo
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
Low
Report
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
3/22
11:19 am
okyo
OKYO Pharma Limited (NASDAQ: OKYO) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.
Low
Report
OKYO Pharma Limited (NASDAQ: OKYO) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.
3/22
07:10 am
okyo
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 [Yahoo! Finance]
High
Report
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 [Yahoo! Finance]
3/22
07:00 am
okyo
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
High
Report
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
3/21
07:17 am
okyo
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial [Yahoo! Finance]
Medium
Report
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial [Yahoo! Finance]
3/21
07:00 am
okyo
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
Medium
Report
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
3/20
07:12 am
okyo
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event [Yahoo! Finance]
High
Report
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event [Yahoo! Finance]
3/20
07:00 am
okyo
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
High
Report
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
2/9
07:15 am
okyo
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain [Yahoo! Finance]
Low
Report
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain [Yahoo! Finance]
2/9
07:00 am
okyo
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
Medium
Report
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
1/31
07:12 am
okyo
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board [Yahoo! Finance]
Medium
Report
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board [Yahoo! Finance]
1/31
07:00 am
okyo
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
Medium
Report
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board